Difference between revisions of "Moxetumomab pasudotox (Lumoxiti)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) | A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) | ||
| − | = | + | ==Diseases for which it is used== |
| − | ==[[Hairy cell leukemia] | + | *[[Hairy cell leukemia]] |
| − | |||
| − | |||
| − | =Also known as= | + | ==History of changes in FDA indication== |
| − | *'''Code | + | *9/13/2018: Initial FDA approval "for adult patients with relapsed or refractory [[Hairy cell leukemia|hairy cell leukemia (HCL)]] who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)." |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code names:''' CAT-8015, HA22 | ||
| + | *'''Brand name:''' Lumoxiti | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 19: | Line 21: | ||
[[Category:Hairy cell leukemia medications]] | [[Category:Hairy cell leukemia medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2018]] |
Revision as of 19:12, 13 September 2018
Mechanism of action
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
Diseases for which it is used
History of changes in FDA indication
- 9/13/2018: Initial FDA approval "for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)."
Also known as
- Code names: CAT-8015, HA22
- Brand name: Lumoxiti